248 related articles for article (PubMed ID: 27485454)
21. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
22. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
[TBL] [Abstract][Full Text] [Related]
23. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
[TBL] [Abstract][Full Text] [Related]
24. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
Beygi S; Sadashiv S; Reilly JB; Khan C; Lister J
Leuk Lymphoma; 2018 Dec; 59(12):2847-2861. PubMed ID: 29616868
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
26. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).
Yoon DH; Sohn BS; Oh SY; Lee WS; Lee SM; Yang DH; Huh J; Suh C
Oncotarget; 2017 Feb; 8(8):13367-13374. PubMed ID: 28076329
[TBL] [Abstract][Full Text] [Related]
28. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Pfreundschuh M; Murawski N; Zeynalova S; Ziepert M; Loeffler M; Hänel M; Dierlamm J; Keller U; Dreyling M; Truemper L; Frickhofen N; Hünerlitürkoglu AN; Schmitz N; Pöschel V; Rixecker T; Berdel C; Rübe C; Held G; Zwick C
Br J Haematol; 2017 Nov; 179(3):410-420. PubMed ID: 28990173
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
30. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
[TBL] [Abstract][Full Text] [Related]
31. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
32. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
[TBL] [Abstract][Full Text] [Related]
33. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
34. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
[TBL] [Abstract][Full Text] [Related]
35. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
Zhang WH; Li GY; Ma YJ; Li ZC; Zhu Y; Chang J; Hao SG; Tao R
Ann Hematol; 2018 Oct; 97(10):1809-1816. PubMed ID: 29754271
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
37. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
38. Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.
Millar A; Ellis M; Mollee P; Cochrane T; Fletcher J; Caudron A; Webster B; Trotman J
Intern Med J; 2015 Nov; 45(11):1147-53. PubMed ID: 26337606
[TBL] [Abstract][Full Text] [Related]
39. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.
Diem S; Ess S; Cerny T; Früh M; Hitz F
Eur J Intern Med; 2014 Jul; 25(6):577-82. PubMed ID: 24881010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
